Erasca Revamps With Two In-Licensings, $160m Follow-On Offering

 
• By Joseph Haas
pancreatic cancer
Erasca is pursuing targeted therapies for solid tumors like pancreatic cancer • Source: Alamy

More from Strategy

More from Business